19 Apr 2026

CRC Research Update — April 19, 2026

Creator: The CRC Digest
Published: 2026-04-19T11:50:04Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Deep Learning Shows High Accuracy for Detecting MSI in Colorectal Cancer
A meta-analysis found that artificial intelligence tools can accurately identify microsatellite instability (MSI-H) in colorectal cancer tissue samples, potentially streamlining testing for patients who may benefit from immunotherapy. (Clinical Colorectal Cancer)
Systematic Review Examines Neoadjuvant Immunotherapy in Localized Rectal Cancer
Researchers reviewed existing studies on using immunotherapy before surgery for localized rectal cancer, providing insights into which patients might benefit from this treatment approach. (Clinical Colorectal Cancer)
First Report of Incomplete Response to Dostarlimab in Rectal Cancer
Clinicians documented a case where dostarlimab immunotherapy did not achieve complete tumor disappearance in locally advanced rectal cancer, highlighting the importance of patient-specific factors in treatment planning and the need for individualized monitoring. (Clinical Colorectal Cancer)
Review Identifies Promising Blood-Based Biomarkers for CRC Screening
A systematic review examined novel blood tests, including circulating tumor DNA (ctDNA), that could help detect colorectal cancer and precancerous conditions earlier through less invasive screening methods. (Clinical Colorectal Cancer)

🧬 Biomarker Spotlight

Research by genetic subtype — MSI-H, ctDNA, and molecular profiling

AI-Based MSI Detection Shows Promise
Meta-analysis confirms deep learning tools can accurately identify MSI-H status, which determines eligibility for immunotherapy. (Clinical Colorectal Cancer)
ctDNA Among Novel Screening Biomarkers
Systematic review highlights circulating tumor DNA as a candidate for blood-based colorectal cancer screening. (Clinical Colorectal Cancer)

🔎 Screening Watch

Advances in early detection and prevention

Blood-Based Screening Biomarkers Under Review
Researchers identified novel blood test candidates that could complement or enhance current colorectal cancer screening approaches. (Clinical Colorectal Cancer)

Research continues to advance our understanding of personalized treatment and early detection — stay informed and discuss new findings with your care team.

CRC Research Update

Subscribe to The CRC Digest